Research programme: autologous T-cell therapies - Adaptimmune

Drug Profile

Research programme: autologous T-cell therapies - Adaptimmune

Alternative Names: Affinity-enhanced T-cell receptors - Adaptimmune; Allogenic T-cell therapies - Adaptimmune; Cytotoxic T-lymphocytes stimulants - Adaptimmune; PRAME; Preferentially expressed antigen in melanoma

Latest Information Update: 01 Jun 2017

Price : $50

At a glance

  • Originator Adaptimmune
  • Class Cell therapies
  • Mechanism of Action Cell replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer
  • Research Diabetes mellitus; Hepatitis C; Immunological disorders

Most Recent Events

  • 25 Apr 2017 Adaptimmune plans a phase I trial for Hepatocellular carcinoma (Late-stage disease, In adults, In the elderly, Second-line therapy or greater) in USA (NCT03132792)
  • 20 Dec 2016 Adaptimmune Therapeutics and Bellicum Pharmaceuticals collaborate to evaluate, develop, and commercialise T-cell therapies
  • 21 Jun 2016 Adaptimmune Therapeutics and Thermo Fischer Scientific enter into a new 10-year agreement for the use of Dynabeads CD3/CD28 Cell Therapy System (CTS™) to manufacture SPEAR™ T-cell therapies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top